Target
venetoclax
5 abstracts
Abstract
FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia,
Abstract
Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy,
Abstract
Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).Org: Novartis Pharma AG, Basel, Switzerland, Novartis Oncology,
Abstract
A real-world evaluation of treatment (Tx) patterns and outcomes of acute myeloid leukemia (AML) induction therapies in the community setting.Org: VCU Massey Cancer Center, Cardinal Health, Bristol Myers Squibb, Cardinal Health Specialty Solutions, Hematology Oncology Associates of CNY,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,